We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

By LabMedica International staff writers
Posted on 22 Mar 2023

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. More...

Despite being highly accurate, the existing diagnostic tests for T2D based on fasting plasma glucose (FPG), oral glucose tolerance test (OGTT) and glycosylated hemoglobin A1c (HbA1c) rely on invasive blood detection. Now, a research team working on a new non-invasive screening method for T2D has used self-developed proton transfer reaction-mass spectrometry (PTR-MS) to detect volatile organic compounds (VOCs) in T2D patients' urine samples.

The research by investigators from the Institute of Health and Medical Technology, Hefei Institutes of Physical Science of the Chinese Academy of Sciences (CAS, Anhui, China) was based on sniffing urinary acetone by PTR-MS. Acetone in urine is one of the ketones produced by fat metabolism. As T2D patients experience insufficient glucose utilization and storage in their blood, their bodies accelerate the metabolism of urinary acetone. In the multicenter study involving 180 T2D patients and 180 healthy individuals, a diagnostic model with an accuracy of 81.3% (sensitivity: 73.3%, specificity: 89.3%) was established by using urinary acetone at center 1, and a threshold of 690.1 ppbv was obtained. The model was subsequently validated in the other two participating centers, yielding similar results. Moreover, the diagnostic accuracy of this approach was found to be on par with the diagnostic method used in the clinic.

"Sniffing T2D through urinary acetone is safe, non-invasive, fast, and accurate," said XU Wei, first author of the paper. "We hope that the method can provide reference for screening and diagnosis of T2D."

Related Links:
Hefei Institutes of Physical Science, CAS


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.